Table 5.

Sensitivity Analysis of Economic Impact on Total PMPM Expenditures for the Use of OVA1 as a Substitute for CA125^a

Model assumptions			Commercially insured			Medicare
Penetration rate, %	Inpatient to outpatient, %	Gynecologic oncologist to gynecologist to avoidance of surgery, %	Current state, $	Future state, $	PMPM change, $	Current state, $	Future state, $	PMPM change, $
10.0	2.5	2.5	2.83	2.81	−0.02	6.34	6.33	−0.01
20.0	5.0	5.0	2.83	2.78	−0.05	6.34	6.33	−0.01
25.0	7.5	7.5	2.83	2.76	−0.07	6.34	6.33	−0.01
30.0	10.0	10.0	2.83	2.74	−0.09	6.34	6.32	−0.02
35.0	12.5	12.5	2.83	2.72	−0.11	6.34	6.32	−0.02
40.0	15.0	15.0	2.83	2.70	−0.13	6.34	6.31	−0.03
45.0	17.5	17.5	2.83	2.68	−0.15	6.34	6.30	−0.04
50.0	20.0	20.0	2.83	2.66	−0.17	6.34	6.29	−0.05

^aCalculations are based on 10 member months annually as reported by OptumInsight.20

PMPM indicates per-member per-month.